GRPR PET imaging for diagnosis and staging of prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional Phase 1/2 imaging study enrolls men with confirmed prostate adenocarcinoma to undergo PET imaging with two novel GRPR-targeting tracers, 68Ga-G21 and 68Ga-G23, and comparison imaging with 68Ga-PSMA-11. Investigators will document tracer biodistribution, safety, and lesion detection across initial staging, biochemical recurrence, and metastatic disease settings. Imaging results will be compared to determine concordance, added lesion detection, and potential complementarity where PSMA expression is low or negative. The protocol focuses on quantifying diagnostic performance and informing whether GRPR PET can guide clinical management in cases where PSMA PET is insufficient.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* confirmed treated or untreated prostate cancer patients;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Where it's running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
• Study coordinator: Weibing Miao, MD
• Email: miaoweibing@126.com
• Phone: 86-0591-87981618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Predicting prostate cancer response to neoadjuvant darolutamide with a gene biomarker

  This study tests whether a gene-based PCAI ImmunoScore can predict which high-risk localized or locally advanced prostate cancer patients will have minimal residual disease after 90–120 days of darolutamide before surgery.

  Recruiting at 2 sites Phase 2 Region Stockholm · Gothenburg and 1 other locations · NCT07617272

• Personal preferences for avoiding gynecomastia (Stage 1)

  This project will ask men with prostate cancer and high-risk biochemical recurrence what trade-offs they'd make to avoid breast-related side effects like gynecomastia.

  Recruiting St Vincent's Hospital, Sydney · Sydney, New South Wales · NCT07552922

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.